Blood biomarkers for personalized treatment and patient management decisions in community-acquired pneumonia

Current Opinion in Infectious Diseases

Volumn 26, Issue 2, 2013, Pages 159-167

  Schuetz, Philipp ^a   Litke, Alexander ^a   Albrich, Werner C ^a   Mueller, Beat ^a  

^a Medical University Clinic   (Switzerland)

Author keywords

Antibiotic stewardship; Biomarker; Community acquired pneumonia; Proadrenomedullin; Procalcitonin

Indexed keywords

ANTIBIOTIC AGENT; C REACTIVE PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; PROADRENOMEDULLIN; PROCALCITONIN; TUMOR NECROSIS FACTOR ALPHA;

ACCURACY; ADVERSE OUTCOME; ALGORITHM; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; COMMUNITY ACQUIRED PNEUMONIA; CURB65 SCORE; DISEASE SEVERITY; FOLLOW UP; HOSPITAL ADMISSION; HUMAN; INTENSIVE CARE UNIT; LENGTH OF STAY; LOWER RESPIRATORY TRACT INFECTION; MEDICAL DECISION MAKING; MORTALITY; PERSONALIZED MEDICINE; PNEUMONIA SEVERITY INDEX; PREDICTION; PREDICTIVE VALUE; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; QUALITY CONTROL; REVIEW; RISK ASSESSMENT; SCORING SYSTEM; TREATMENT DURATION; UPREGULATION; VIRAL RESPIRATORY TRACT INFECTION;

ADRENOMEDULLIN; ANTI-BACTERIAL AGENTS; BIOLOGICAL MARKERS; CALCITONIN; COMMUNITY-ACQUIRED INFECTIONS; HUMANS; PNEUMONIA; PROTEIN PRECURSORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEVERITY OF ILLNESS INDEX;

EID: 84874939867     PISSN: 09517375     EISSN: 14736527     Source Type: Journal    
DOI: 10.1097/QCO.0b013e32835d0bec     Document Type: Review

References (69)

1. Woodhead M, Blasi F, Ewig S, et al. Guidelines for the management of adult lower respiratory tract infections. Clin Microbiol Infect 2011; 17 (Suppl 6): E1-E59.
2. Levy MM, Fink MP, Marshall JC, et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med 2003; 31:1250-1256. (Pubitemid 36444440)
3. Rivers E, Nguyen B, Havstad S, et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 2001; 345:1368-1377.
4. Kumar A, Haery C, Paladugu B, et al. The duration of hypotension before the initiation of antibiotic treatment is a critical determinant of survival in a murine model of Escherichia coli septic shock: association with serum lactate and inflammatory cytokine levels. J Infect Dis 2006; 193:251-258. (Pubitemid 43113487)
5. Puskarich MA, Trzeciak S, Shapiro NI, et al. Association between timing of antibiotic administration and mortality from septic shock in patients treated with a quantitative resuscitation protocol. Crit Care Med 2011; 39:2066-2071.
6. Vincent JL. Dear SIRS, I'm sorry to say that I don't like you. Crit Care Med 1997; 25:372-374.
7. Niederman MS, Mandell LA, Anzueto A, et al. Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med 2001; 163:1730-1754. (Pubitemid 32578779)
8. Aliyu ZY, Aliyu MH, McCormick K. Determinants for hospitalization in 'low-risk' community acquired pneumonia. BMC Infect Dis 2003; 3:11.
9. Chalmers JD, Al-Khairalla M, Short PM, et al. Proposed changes to management of lower respiratory tract infections in response to the Clostridium difficile epidemic. J Antimicrob Chemother 2010 ;65:608-618.
10. Fried TR, van Doorn C,O'Leary JR, et al. Older person's preferences for home vs hospital care in the treatment of acute illness. Arch Intern Med 2000; 160:1501-1506. (Pubitemid 30327455)
11. Bahni C, Meier S, Spreiter P, et al. Which patients with lower respiratory tract infections need inpatient treatment? Perceptions of physicians, nurses, patients and relatives. BMC Pulm Med 2010; 10:12.
12. Schuetz P, Christ-Crain M, Thomann R, et al. Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial. JAMA 2009; 302:1059-1066.
13. Yealy DM, Auble TE, Stone RA, et al. Effect of increasing the intensity of implementing pneumonia guidelines: a randomized, controlled trial. Ann Intern Med 2005; 143:881-894. (Pubitemid 46205946)
14. Huang DT, Weissfeld LA, Kellum JA, et al. Risk prediction with procalcitonin and clinical rules in community-acquired pneumonia. Ann Emerg Med 2008; 52:48-58; e42.
15. Loeb M, Carusone SC, Goeree R, et al. Effect of a clinical pathway to reduce hospitalizations in nursing home residents with pneumonia: a randomized controlled trial. JAMA 2006; 295:2503-2510. (Pubitemid 43854965)
16. Marrie TJ, Lau CY, Wheeler SL, et al. A controlled trial of a critical pathway for treatment of community-acquired pneumonia. CAPITAL study investigators. Community-acquired pneumonia intervention trial assessing levofloxacin. JAMA 2000; 283:749-755.
17. Christ-Crain M,Muller B. Biomarkers in respiratory tract infections: diagnostic guides to antibiotic prescription, prognostic markers and mediators. Eur Respir J 2007; 30:556-573. (Pubitemid 351182082)
18. Schuetz P, Haubitz S, Mueller B. Do sepsis biomarkers in the emergency room allow transition from bundled sepsis care to personalized patient care? Curr Opin Crit Care 2012; 18:341-349.
19. Kumar A, Roberts D, Wood KE, et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006; 34:1589-1596. (Pubitemid 43810035)
20. Ohl CA, Luther VP. Antimicrobial stewardship for inpatient facilities. J Hosp Med 2011; 6 (Suppl 1):S4-S15.
21. Lawrence KL, Kollef MH. Antimicrobial stewardship in the intensive care unit: advances and obstacles. Am J Respir Crit Care Med 2009; 179:434-438.
22. Schuetz P, Christ-Crain M, Muller B. Procalcitonin and other biomarkers to improve assessment and antibiotic stewardship in infections:hope for hype? Swiss Med Wkly 2009; 139:318-326.
23. Muller B, White JC, Nylen ES, et al. Ubiquitous expression of the calcitonin-i gene in multiple tissues in response to sepsis. J Clin Endocrinol Metab 2001; 86:396-404. (Pubitemid 32109825)
24. Muller F, Christ-Crain M, Bregenzer T, et al. Procalcitonin levels predict bacteremia in patients with community-acquired pneumonia: a prospective cohort trial. Chest 2010; 138:121-129.
25. Becker KL. Procalcitonin and the calcitonin gene family of peptides in inflammation, infection, and sepsis: a journey from calcitonin back to its precursors. J Clin Endocrinol Metab 2004; 89:1512-1525. (Pubitemid 38507896)
26. Linscheid P, Seboek D, Zulewski H, et al. Autocrine/paracrine role of inflammation-mediated calcitonin gene-related peptide and adrenomedullin expression in human adipose tissue. Endocrinology 2005; 146:2699-2708. (Pubitemid 40695573)
27. Linscheid P, Seboek D, Schaer DJ, et al. Expression and secretion of procalcitonin and calcitonin gene-related peptide by adherent monocytes and by macrophage-activated adipocytes. Crit Care Med 2004; 32:1715-1721. (Pubitemid 39050523)
28. Schuetz P, Chiappa V, Briel M, Greenwald JL. Procalcitonin algorithms for antibiotic therapy decisions: a systematic review of randomized controlled trials and recommendations for clinical algorithms. Arch Intern Med 2011; 171:1322-1331.
29. Schuetz P, Muller B, Christ-Crain M, et al. Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections. Cochrane Database Syst Rev 2012; 9:CD007498.
30. Schuetz P, Briel M, Christ-Crain M, et al. Procalcitonin to guide initiation and duration of antibiotic treatment in acute respiratory infections: an individual patient data meta-analysis. Clin Infect Dis 2012; 55:651-662.
31. Bouadma L, Luyt CE, Tubach F, et al. Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial. Lancet 2010; 375:463-474.
32. Nobre V, Harbarth S, Graf JD, et al. Use of procalcitonin to shorten antibiotic treatment duration in septic patients: a randomized trial. Am J Respir Crit Care Med 2007; 177:498-505. (Pubitemid 351442188)
33. Schuetz P, Batschwaroff M, Dusemund F, et al. Effectiveness of a procalcitonin algorithm to guide antibiotic therapy in respiratory tract infections outside of study conditions: a poststudy survey. Eur J Clin Microbiol Infect Dis 2010; 29:269-277.
34. Albrich WC, Dusemund F, Bucher B, et al. Effectiveness and safety of procalcitonin-guided antibiotic therapy in lower respiratory tract infections in 'real life': an international, multicenter poststudy survey (ProREAL). Arch Intern Med 2012; 172:715-722.
35. Woodhead M, Blasi F, Ewig S, et al. Guidelines for the management of adult lower respiratory tract infections. Eur Respir J 2005; 26:1138-1180. (Pubitemid 41829947)
36. Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997; 336:243-250. (Pubitemid 27044625)
37. Lim WS, Macfarlane JT, Boswell TC, et al. Study of community acquired pneumonia aetiology (SCAPA) in adults admitted to hospital: implications for management guidelines. Thorax 2001; 56:296-301. (Pubitemid 32269810)
38. Lim WS, van der Eerden MM, Laing R, et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax 2003; 58:377-382. (Pubitemid 36560938)
39. Morgenthaler NG, Struck J, Christ-Crain M, et al. Pro-atrial natriuretic peptide is a prognostic marker in sepsis, similar to the APACHE II score: an observational study. Crit Care 2005; 9:R37-45.
40. Christ-Crain M, Morgenthaler NG, Struck J, et al. Mid-regional pro-adrenomedullin as a prognostic marker in sepsis: an observational study. Crit Care 2005; 9:R816-824.
41. Christ-Crain M, Morgenthaler NG, Stolz D, et al. Pro-adrenomedullin to predict severity and outcome in community-acquired pneumonia (ISRCTN04176397). Crit Care 2006; 10:R96.
42. Muller B, Suess E, Schuetz P, et al. Circulating levels of pro-atrial natriuretic peptide in lower respiratory tract infections. J Intern Med 2006; 260:568-576. (Pubitemid 44772377)
43. Muller B, Morgenthaler N, Stolz D, et al. Circulating levels of copeptin, a novel biomarker, in lower respiratory tract infections. Eur J Clin Invest 2007; 37:145-152. (Pubitemid 46066494)
44. Christ-Crain M, Jutla S, Widmer I, et al. Measurement of serum free cortisol shows discordant responsivity to stress and dynamic evaluation. J Clin Endocrinol Metab 2007; 92:1729-1735. (Pubitemid 46997179)
45. Stolz D, Christ-Crain M, Morgenthaler NG, et al. Copeptin, C-reactive protein, and procalcitonin as prognostic biomarkers in acute exacerbation of COPD. Chest 2007; 131:1058-1067. (Pubitemid 46608707)
46. Morgenthaler NG, Muller B, Struck J, et al. Copeptin, a stable peptide of the arginine vasopressin precursor, is elevated in hemorrhagic and septic shock. Shock 2007; 28:219-226. (Pubitemid 47220835)
47. Christ-Crain M, Stolz D, Jutla S, et al. Free and total cortisol levels as predictors of severity and outcome in community-acquired pneumonia. Am J Respir Crit Care Med 2007; 176:913-920. (Pubitemid 350097081)
48. Christ-Crain M, Muller B. Biomarkers in respiratory tract infections: diagnostic guides to antibiotic prescription, prognostic markers and mediators. Eur Respir J 2007; 30:556-573. (Pubitemid 351182082)
49. Schuetz P, Christ-Crain M, Muller B. Biomarkers to improve diagnostic and prognostic accuracy in systemic infections. Curr Opin Crit Care 2007; 13:578-585. (Pubitemid 47357461)
50. Morgenthaler NG, Struck J, Alonso C, Bergmann A. Measurement of midregional proadrenomedullin in plasma with an immunoluminometric assay. Clin Chem 2005; 51:1823-1829. (Pubitemid 41368172)
51. Eto T. A review of the biological properties and clinical implications of adrenomedullin and proadrenomedullin N-terminal 20 peptide (PAMP), hypotensive and vasodilating peptides. Peptides 2001; 22:1693-1711. (Pubitemid 34062786)
52. von Haehling S, Filippatos GS, Papassotiriou J, et al. Mid-regional proadrenomedullin as a novel predictor of mortality in patients with chronic heart failure. Eur J Heart Fail 2010; 12:484-491.
53. Schuetz P, Wolbers M, Christ-Crain M, et al. Prohormones for prediction of adverse medical outcome in community-acquired pneumonia and lower respiratory tract infections. Crit Care 2010; 14:R106.
54. Maisel A, Mueller C, Nowak R, et al. Mid-region pro-hormone markers for diagnosis and prognosis in acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trial. J Am Coll Cardiol 2010; 55:2062-2076.
55. Vila G, Riedl M, Maier C, et al. Plasma MR-proADM correlates to BMI and decreases in relation to leptin after gastric bypass surgery. Obesity (Silver Spring) 2009; 17:1184-1188.
56. Stolz D, Christ-Crain M, Morgenthaler NG, et al. Plasma pro-adrenomedullin but not plasma pro-endothelin predicts survival in exacerbations of COPD. Chest 2008; 134:263-272.
57. Christ-Crain M, Morgenthaler NG, Struck J, et al. Mid-regional pro-adrenomedullin as a prognostic marker in sepsis: an observational study. Crit Care 2005; 9:R816-824.
58. Christ-Crain M, Morgenthaler NG, Stolz D, et al. Pro-adrenomedullin to predict severity and outcome in community-acquired pneumonia (ISRCTN04176397). Crit Care 2006; 10:R96.
59. Krüger S, Ewig S, Giersdorf S, et al. Cardiovascular and inflammatory biomarkers to predict short- and long-term survival in community-acquired pneumonia: results from the German Competence Network, CAPNETZ. Am J Respir Crit Care Med 2010; 182:1426-1434.
60. Albrich WC, Dusemund F, Ruegger K, et al. Enhancement of CURB65 score with proadrenomedullin (CURB65-A) for outcome prediction in lower respiratory tract infections: derivation of a clinical algorithm. BMC Infect Dis 2011; 11:112.
61. Guertler C, Wirz B, Christ-Crain M, et al. Inflammatory responses predict longterm mortality risk in community-acquired pneumonia. Eur Respir J 2011; 37:1439-1446.
62. Huang DT, Angus DC, Kellum JA, et al. Midregional proadrenomedullin as a prognostic tool in community-acquired pneumonia. Chest 2009; 136:823-831.
63. Courtais C, Kuster N, Dupuy AM, et al. Proadrenomedullin, a useful tool for risk stratification in high Pneumonia Severity Index score community acquired pneumonia. Am J Emerg Med 2013, 31:215-221.
64. Bello S, Lasierra AB, Minchole E, et al. Prognostic power of proadrenomedullin in community-acquired pneumonia is independent of aetiology. Eur Respir J 2012; 39:1144-1155.
65. Renaud B, Schuetz P, Claessens YE, et al. Proadrenomedullin improves REAICU score for predicting early severe community-acquired pneumonia. Chest 2012. [Epub ahead of print]
66. Suberviola B, Castellanos-Ortega A, Llorca J, et al. Prognostic value of proadrenomedullin in severe sepsis and septic shock patients with community-acquired pneumonia. Swiss Med Wkly 2012; 142: w13542.
67. Phua J, Ngerng WJ, Lim TK. The impact of a delay in intensive care unit admission for community-acquired pneumonia. Eur Respir J 2010; 36:826-833.
68. Renaud B, Santin A, Coma E, et al. Association between timing of intensive care unit admission and outcomes for emergency department patients with community-acquired pneumonia. Crit Care Med 2009; 37:2867-2874.
69. Albrich WC, Ruegger K, Dusemund F, et al. Optimised patient transfer using an innovative multidisciplinary assessment in Kanton Aargau (OPTIMA I): an observational survey in lower respiratory tract infections. Swiss Med Wkly 2011; 141:w13237.